The most common side effects of fingolimod have been head colds, headache, and fatigue. A few cases of skin cancer have been reported, which has also been reported in patients taking [[natalizumab]] (Tysabri), an approved MS drug.<ref>{{cite web|url=http://www.webmd.com/multiple-sclerosis/news/20080416/good-news-for-oral-ms-drug-fingolimod |title=Good News for Oral MS Drug Fingolimod |publisher=Webmd.com |date=2008-04-16 |accessdate=2013-09-30}}</ref> Fingolimod has also been associated with potentially fatal infections, bradycardia and, recently, a case of hemorrhaging focal [[encephalitis]], an inflammation of the brain with bleeding.<ref>{{vcite2 journal |vauthors=Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C |title=Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report |journal=Neurology |volume=72 |issue=11 |pages=1022–4 |year=2009 |pmid= 19289744|doi=10.1212/01.wnl.0000344567.51394.e3}}</ref> Two people died: one due to brain herpes infection, and a second one due to [[zoster]]. It is unclear whether the drug was responsible for the events.<ref>http://www.ms-uk.org/dmd?flap=6#6</ref> At least three cases of [[progressive multifocal leukoencephalopathy]] had also occurred as of 2015.<ref>{{cite web|last=Brooks|first=Megan|title=Third Case of PML With Fingolimod (Gilenya) in MS|url=http://www.medscape.com/viewarticle/849677|website=Medscape|accessdate=2015-08-20|date=2015-08-18}}</ref>

 


 
Fingolimod has also been known to cause [[macular edema]], resulting in decreased vision.<ref>{{vcite2 journal |vauthors=Jain N, Bhatti MT |title=Fingolimod-associated macular edema: incidence, detection, and management |journal=Neurology |volume=78 |issue=9 |pages=672–80 |year=2012 |pmid=22371414 |doi=10.1212/WNL.0b013e318248deea}}</ref><ref>{{vcite2 journal |vauthors=Jain N, Bhatti MT |title=Macular Edema Associated With Fingolimod |journal=EyeNet |date=April 2012 |url=http://development.aao.org/publications/eyenet/201204/upload/Fingolimod-Associated-Macular-Edema-PDF.pdf}}</ref>

 


 
The [[European Medicines Agency]] has advised doctors to increase their level of monitoring of people after the first dose of the medicine. This includes electrocardiogram (ECG) monitoring before treatment and then continuously for the first six hours after the first dose, and measurement of blood pressure and heart rate every hour.<ref>{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/01/news_detail_001425.jsp&mid=WC0b01ac058004d5c1 |title=European Medicines Agency - News and Events - European Medicines Agency starts review of Gilenya (fingolimod) |publisher=Ema.europa.eu |date=2012-01-20 |accessdate=2013-09-30}}</ref>

 

